Munich, Germany — October 6, 2025 — CPTx today announced the presentation at the Annual Meeting of the European Society for Gene and Cell Therapy of new data supporting the company’s differentiated “third path” approach to in vivo CAR T treatments for oncology. Unlike viral vectors that permanently integrate into the genome or mRNA approaches that may fade too quickly for oncology, CPTx’s in vivo CAR T treatments, built with single-stranded DNA (ssDNA) delivered by targeted lipid nanoparticles (LNPs), are designed to be redosable, duration-controlled, and immune-silent.
“We have overcome key barriers of DNA innate immune activation and nuclear delivery, unlocking DNA for the first time as a viable non-viral vector for immune cell therapies,” said Hendrik Dietz, CEO of CPTx. “Our single-stranded DNA vectors enable efficient gene expression while bypassing immune detection, and our proprietary LNPs, which are optimized for ssDNA delivery, are achieving industry-leading DNA T-cell transfection.”
ssDNA provides tunable control over the duration of gene expression in immune cells, which is a critical parameter for therapeutic breadth, and opens therapeutic opportunities across oncology and autoimmune diseases. CPTx’s lead program is an in vivo CD19/CD20 dual-targeting CAR T for relapsed/refractory B-NHL. The company anticipates initiation of a first clinical trial within 15–18 months.
CPTx is presenting three posters at ESGCT highlighting innovations in ssDNA structural design (to support nuclear entry and expression), proprietary tLNPs for immune-cell delivery, and scalable manufacturing which position the company to unlock in vivo CAR T and other genetic medicine applications that benefit from ongoing control over dose and expression, not “one-and-done” edits.
- P0953 (Maufacturing): “Scalable manufacturing of ssDNA templates suitable for high-efficiency gene knock-ins in primary human T-cells”
- P1009 (Non-viral delivery): “Single-stranded DNA as a versatile non-viral platform for targeted gene knock-in and transient gene expression”
- P1040 (Non-viral delivery): “Single-Stranded DNA as a Novel Vector Platform for Safer and Less Immunogenic Gene Delivery”
About CPTx
CPTx is redefining the future of genetic medicine through a single-stranded DNA (ssDNA) platform that enables safer, redosable, and scalable gene therapies.
CPTx’s lead proprietary development program is a new kind of in vivo CAR T-cell therapy using immune-silent single-stranded DNA delivered with LNPs, enabling repeat dosing, and controllable, long-lasting effects, something not possible with viral vectors or mRNA.
Learn more at cptx.bio or contact info@cptx.bio.
Contacts:
CPTx investors
McDavid Stilwell
CFO
mcdavid.stilwell@cptx.bio
Media
Beth Willers
WMC
bethw@whitemattercomm.com